Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Five-Year Longitudinal MRI Follow-up and (1)H Single Voxel MRS in 14 patients with Gliomatosis Treated with Temodal, Radiotherapy and Antiangiogenic Therapy.

Constans JM, Collet S, Kauffmann F, Hossu G, Dou W, Ruan S, Rioult F, Derlon JM, Lechapt-Zalcmann E, Chapon F, Valable S, Théron J, Guillamo JS, Courthéoux P.

Neuroradiol J. 2011 Jun 30;24(3):401-14. Epub 2011 Jun 24.

PMID:
24059663
2.

Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling.

Huang J, Wang AM, Shetty A, Maitz AH, Yan D, Doyle D, Richey K, Park S, Pieper DR, Chen PY, Grills IS.

Magn Reson Imaging. 2011 Sep;29(7):993-1001. doi: 10.1016/j.mri.2011.04.004. Epub 2011 May 14.

PMID:
21571478
3.
4.

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.

Guillevin R, Menuel C, Taillibert S, Capelle L, Costalat R, Abud L, Habas C, De Marco G, Hoang-Xuan K, Chiras J, Vallée JN.

Br J Cancer. 2011 Jun 7;104(12):1854-61. doi: 10.1038/bjc.2011.174. Epub 2011 May 24.

5.

Serial proton magnetic resonance spectroscopy in lesions of Balò concentric sclerosis.

Chen CJ.

J Comput Assist Tomogr. 2001 Sep-Oct;25(5):713-8.

PMID:
11584230
6.

Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.

Hsieh TJ, Li CW, Chuang HY, Liu GC, Wang CK.

J Comput Assist Tomogr. 2008 Nov-Dec;32(6):987-94. doi: 10.1097/RCT.0b013e31815b9ce9.

PMID:
19204465
7.

Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors.

Server A, Josefsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar Ø, Kumar T, Haakonsen M, Langberg CW, Nakstad PH.

Acta Radiol. 2010 Apr;51(3):316-25. doi: 10.3109/02841850903482901.

PMID:
20092374
8.

Metabolic approach for tumor delineation in glioma surgery: 3D MR spectroscopy image-guided resection.

Zhang J, Zhuang DX, Yao CJ, Lin CP, Wang TL, Qin ZY, Wu JS.

J Neurosurg. 2016 Jun;124(6):1585-93. doi: 10.3171/2015.6.JNS142651. Epub 2015 Dec 4.

PMID:
26636387
9.

First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.

Seiz M, Kohlhof P, Brockmann MA, Neumaier-Probst E, Hermes P, VON Deimling A, Vajkoczy P, Schmieder K, Tuettenberg J.

Anticancer Res. 2009 Aug;29(8):3261-7.

10.

[Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report].

Inoue T, Kanamori M, Sonoda Y, Watanabe M, Sasajima T, Kamisato N, Kumabe T, Tominaga T.

No Shinkei Geka. 2008 Aug;36(8):709-15. Review. Japanese.

PMID:
18700534
11.

Spectral changes in postoperative MRS in high-grade gliomas and their effect on patient prognosis.

Czernicki T, Szeszkowski W, Marchel A, Gołebiowski M.

Folia Neuropathol. 2009;47(1):43-9.

12.

Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: a pilot study.

Bladowska J, Zimny A, Knysz B, Małyszczak K, Kołtowska A, Szewczyk P, Gąsiorowski J, Furdal M, Sąsiadek MJ.

J Hepatol. 2013 Oct;59(4):651-7. doi: 10.1016/j.jhep.2013.05.008. Epub 2013 May 13.

PMID:
23680314
13.

Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma.

Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barrie-Attarian M, Ranjeva JP, Fuentès S, Viout P, Figarella-Branger D, Cozzone PJ.

J Neurosurg. 2003 Feb;98(2):269-76.

PMID:
12593610
14.

Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.

Fink JR, Carr RB, Matsusue E, Iyer RS, Rockhill JK, Haynor DR, Maravilla KR.

J Magn Reson Imaging. 2012 Jan;35(1):56-63. doi: 10.1002/jmri.22801. Epub 2011 Oct 14.

PMID:
22002882
15.

Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.

Lodi R, Setola E, Tonon C, Ambrosetto P, Franceschi E, Crinò L, Barbiroli B, Cortelli P.

Magn Reson Imaging. 2003 Nov;21(9):1003-7.

PMID:
14684203
16.

Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.

Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, Naegele T, Ernemann U.

Invest Radiol. 2013 May;48(5):295-301. doi: 10.1097/RLI.0b013e31827188d6.

PMID:
23296081
17.

[Gliomatosis cerebri].

Sanson M, Napolitano M, Cartalat-Carel S, Taillibert S.

Rev Neurol (Paris). 2005 Feb;161(2):173-81. Review. French.

PMID:
15798516
18.

Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.

Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le TP, Lu Y, Nelson S, McKnight TR.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31.

PMID:
15850898
19.

Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma.

Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B, Riauka T, Hanson J, Fulton D, McEwan A, Roa W.

Clin Invest Med. 2006 Oct;29(5):301-11.

PMID:
17144440
20.

[Can proton magnetic resonance spectroscopy be of any value as a prognostic factor in medulloblastoma?].

Dembowska-Bagińska B, Perek D, Perek-Polnik M, Drogosiewicz M, Jurkiewicz E, Pakuła-Kościesza I, Grajkowska W, Roszkowski M.

Med Wieku Rozwoj. 2003 Apr-Jun;7(2):229-39. Polish.

PMID:
12878794

Supplemental Content

Support Center